Skip to main content
OpenTrials

Clinical trial condition

Diphtheria-Tetanus-acellular Pertussis Vaccines

Explore clinical trials studying Diphtheria-Tetanus-acellular Pertussis Vaccines. Study availability and eligibility vary by location and protocol.

10 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Diphtheria-Tetanus-acellular Pertussis Vaccines trial results

Recruiting

A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years

NCT07596173

Conditions
Diphtheria-Tetanus-acellular Pertussis Vaccines
Locations
  • GSK Investigational Site Fukuoka, Japan
  • GSK Investigational Site Hokkaido, Japan
  • GSK Investigational Site Hokkaido, Japan
  • GSK Investigational Site Hokkaido, Japan
View Trial Details
Recruiting

A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women

NCT07596199

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +7 more
Locations
  • GSK Investigational Site Chiba, Japan
  • GSK Investigational Site Fukui, Japan
  • GSK Investigational Site Fukushima, Japan
  • GSK Investigational Site Hokkaido, Japan
View all 18 locations
View Trial Details
Completed

Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects

NCT03311659

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +12 more
Locations
  • GSK Investigational Site Barnaul, Russia
  • GSK Investigational Site Gatchina, Russia
  • GSK Investigational Site Moscow, Russia
  • GSK Investigational Site Moscow, Russia
View Trial Details
Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women

NCT02377349

Conditions
Diphtheria-Tetanus-acellular Pertussis Vaccines
Locations
  • GSK Investigational Site Carlton, Victoria, Australia
  • GSK Investigational Site Fitzroy, Victoria, Australia
  • GSK Investigational Site Parkville, Victoria, Australia
  • GSK Investigational Site Calgary, Alberta, Canada
View all 35 locations
View Trial Details
Completed

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

NCT00835237

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +8 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site DeLand, Florida, United States
  • GSK Investigational Site West Palm Beach, Florida, United States
View all 24 locations
View Trial Details

Related conditions